Abstract:
MATERIALS AND METHODS
This randomized controlled trial was conducted at Tashkent Medical Academy from December 20, 2023, to November 27, 2024, in accordance with the CONSORT guidelines. Ethical approval was obtained from the Institutional Review Board, and all participants provided written informed consent.
Inclusion criteria were:
* Age 18-40 years;
* Singleton intrauterine pregnancy confirmed by ultrasound;
* Gestational age between 6 and 21 weeks;
* Diagnosis of threatened miscarriage with bleeding and/or cramping, closed cervix, and no fetal tissue expulsion;
* Willingness to comply with study protocols.
Exclusion criteria included: spontaneous or missed miscarriage, ectopic pregnancy, fetal anomalies, multiple gestations, history of preterm labor, uterine malformations, contraindications to progesterone, and inability to follow the regimen.
